We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Determining Fibrosis Stage in Non-Alcoholic Fatty Liver Disease

By LabMedica International staff writers
Posted on 24 Sep 2018
Measurement of a specific biomarker identifies advanced fibrosis in patients with non-alcoholic fatty liver disease.

Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver, which occurs when fat is deposited (steatosis) in the liver due to causes other than excessive alcohol use. Given the high global prevalence of NAFLD, the need for relevant non‐invasive biomarkers and algorithms to accurately stage disease severity is a critical unmet medical need. Identifying those with advanced fibrosis is the most crucial, as these individuals have the greatest risk of adverse, long‐term, liver‐related outcomes.

Image: A micrograph of non-alcoholic fatty liver disease, demonstrating marked steatosis (fatty liver appears white) (Photo courtesy of Wikimedia Commons).
Image: A micrograph of non-alcoholic fatty liver disease, demonstrating marked steatosis (fatty liver appears white) (Photo courtesy of Wikimedia Commons).

In an effort to establish a diagnostic test, investigators at Westmead Institute for Medical Research (Australia) evaluated the role of PRO‐C3 (a marker of type III collagen formation) as a biomarker for advanced fibrosis in NAFLD.

The investigators measured PRO‐C3 by enzyme‐linked immunosorbent assay (ELISA) in two large independent cohorts with extensive clinical phenotyping and liver biopsy; 150 in the derivation and 281 in the validation cohort. A PRO‐C3 based fibrosis algorithm (ADAPT) was developed that included age, presence of diabetes, PRO‐C3, and platelet count.

Results revealed that PRO‐C3 increased with fibrosis stage and was independently associated with advanced fibrosis. Findings, as interpreted by the ADAPT algorithm, accurately identified 92% of patients with advanced fibrosis and were superior to the existing fibrosis scores, aspartate aminotransferase (AST) to platelet ratio index (APRI), FIB‐4 and NAFLD fibrosis score (NFS).

"Given the high global prevalence of non-alcoholic fatty liver disease, we need a non-invasive clinical tool to accurately measure fibrosis," said senior author Dr. Jacob George, professor of gastroenterology at Westmead Institute for Medical Research. The tool would help to identify patients at greatest risk poor long-term health outcomes."

The study was published in the July 16, 2018, online edition of the journal Hepatology.

Related Links:
Westmead Institute for Medical Research


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
New
Portable POCT Blood Gas Analyzer
BD100

Latest Molecular Diagnostics News

New PCR Assays Expand Cyclospora Testing for Outbreak Surveillance
24 Sep 2018  |   Molecular Diagnostics

Single Liquid Biopsy Predicts Early Immunotherapy Benefit in Advanced Lung Cancer
24 Sep 2018  |   Molecular Diagnostics

Machine Learning Tool Improves Prediction of Liver Cancer Recurrence
24 Sep 2018  |   Molecular Diagnostics